RxDoctor Payments Data

Eric Heller, MD

Cardiovascular Disease · Delray Beach, FLNPI 1073764718

Payments from drug & device makers

$23,834in general payments, 2019–2025

Across 456 payments — averaging $52.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Abbott$5K
  • Novartis$971
  • Boston Scientific$705
  • Edwards Lifesciences$603
  • Amgen$545
  • plus $5K from 40 others

What the payments were for

  • Grants$3,33314%
  • Travel & lodging$2,79112%
  • Food & beverage$10,46644%
  • Education$2241%
  • Other$7,01929%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,834 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$2,255,331
Medicare patients
1,634
Services billed
24,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban448$584,848
XareltoRivaroxaban241$301,814
Repatha SureclickEvolocumab178$231,589
EntrestoSacubitril/Valsartan124$175,240
FarxigaDapagliflozin Propanediol159$170,894
MultaqDronedarone Hcl75$128,477
BrilintaTicagrelor89$78,755
VascepaIcosapent Ethyl78$61,274
Praluent PenAlirocumab49$48,970
JardianceEmpagliflozin23$35,497
Icosapent Ethyl29$13,000
Rosuvastatin Calcium986$12,898
OzempicSemaglutide13$12,033
Repatha SyringeEvolocumab11$11,519
Valsartan329$10,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$317$584,848448 claims
Johnson & JohnsonXarelto$481$301,814241 claims
AstraZenecaFarxiga, Brilinta$307$249,649248 claims
NovartisEntresto$971$175,240124 claims
Sanofi-aventis U.S. LLCMultaq$443$128,47775 claims
Boehringer IngelheimJardiance$350$35,49723 claims
Novo NordiskOzempic$168$12,03313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →